134 PART THREE | DELIRIUM References 1. Caraceni A, Grassi L. Delirium: acute confusional states in palliative medicine. 2nd ed. Oxford: Oxford University Press, 2011. 2. Hosie A, Davidson PM, Agar M et al. Delirium prevalence, incidence, and implications for screening in specialist palliative care inpatient settings: a systematic review. Palliat Med 2013;27:486-98. 3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Arlington American Psychiatric Association 2013. Available at https://www.psychiatry. org/psychiatrists/practice/dsm. (22 March 2019, date last accessed). 4. Caraceni A, Nanni O, Maltoni M et al. Impact of delirium on the short-term prognosis of advanced cancer patients. Italian Multicenter Study Group on Palliative Care. Cancer 2000;89:1145-9. 5. Lawlor PG, Bush SH. Delirium in patients with cancer: assessment, impact, mechanisms and management. Nat Rev Clin Oncol 2015;12:77-9. 6. Breitbart W, Gibson C, Tremblay A. The delirium experience: Delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses/caregivers, and their nurses. Psychosomatics 2002;43:183-94. 7. Bruera E, Bush SH, Willey J et al. Impact of delirium and recall on the level of distress in patients with advanced cancer and their family caregivers. Cancer 2009;115:200412. 8. Bush SH, Lawlor PG, Ryan K et al. Delirium in adult cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2018;29 (Suppl 4): iv143–iv165. 9. Burry L, Mehta S, Perreault MM et al. Antipsychotics for treatment of delirium in hospitalized non-ICU patients. Cochrane Database Syst Rev. 2018. Available at https://www.cochranelibrary.com/cdsr/ doi/10.1002/14651858.CD005594/epdf/ full. (22 March 2019, date last accessed). 10. National Clinical Guideline Centre. Delirium: diagnosis, prevention and management. Clinical Guideline 103. NCGC, 2010. Available at https://www. nice.org.uk/CG103 (22 March 2019, date last accessed). 11. National Comprehensive Cancer Network. NCCN Clinical Practice guidelines in Oncology: Palliative care, Version 2.2013. Delirium PAL-21. USA: National Comprehensive Cancer Network (NCCN), 2013. Available at https://www.nccn.org/ professionals/physician_gls/default.aspx. (22 March 2019, date last accessed). 12. Kishi T, Hirota T, Matsunaga S, Iwata N. Antipsychotic medications for the treatment of delirium: a systematic review and meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry 2016;87:767-74. 13. Lin CJ, Sun FJ, Fang CK et al. An open trial comparing haloperidol with olanzapine for the treatment of delirium in palliative and hospice center cancer patients. J Int Med Taiwan 2008;19:345-54. 14. Maneeton B, Maneeton N, Srisurapanont M, Chittawatanarat K. Quetiapine versus haloperidol in the treatment of delirium: a double-blind, randomized, controlled trial. Drug Des Devel Ther. 2013;24:657-67. 15. Agar MR, Lawlor PG, Quinn S, et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Intern Med 2017;177:34-42.
RkJQdWJsaXNoZXIy MjY0ODMw